[ad_1]
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (NASDAQ: ZYME) is a clinical-stage biotechnology company developing multiple novel multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases. Cure Disease, announced today that management will participate in the following upcoming investor meetings:
-
twenty threeRD Annual Needham Virtual Healthcare Conference: Zymeworks Management to Participate in Virtual One-on-One Meetings and Present on April 11th 11:45 a.m. ET.
-
Canaccord Genuity Horizons in Oncology Virtual Meeting: Zymeworks management will participate in virtual one-on-one meetings and panel discussions on April 15th 3:00 p.m. ET.
-
Stifel Virtual Targeted Oncology Day: Zymeworks management will participate in virtual one-on-one meetings and be present on April 16th 12:30 p.m. ET.
-
2024 Bloom Burton & Co. Healthcare Investor Conference: Zymeworks Management to Participate in One-on-One Meetings and Present on April 16th 2:00 p.m. ET.
All presentations and webcasts will be available on the Zymeworks website: http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Corporation
Zymeworks is a global biotechnology company engaged in the discovery, development and commercialization of novel multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people affected by difficult-to-treat cancer and other diseases. The company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely design and develop highly differentiated antibody-based therapeutic candidates. Zymeworks designed and developed zanidatamab, a bispecific antibody targeting HER2, using the company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene and Jazz Pharmaceuticals Ireland Limited (Jazz) granting each exclusive rights to develop and commercialize zanidatamab in separate territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. Leveraging its experience and capabilities in antibody-drug conjugates and multispecific antibody therapeutics, Zymeworks is rapidly advancing a pipeline of product candidates across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platform is further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
contact method:
Investor enquiries:
Inandar Temple
Director of Investor Relations
(604)678-1388
ir@zymeworks.com
Media enquiries:
Diana Papov
Senior Director of Corporate Communications
(604)678-1388
media@zymeworks.com
[ad_2]
Source link